Company intelligence / Profile preview

Spektus Pharma Inc.

Montreal, Quebec, Canadaspektuspharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

Spektus Pharma develops value-added CNS medicines using its proprietary Flexitab™ platform to create breakable extended-release tablets. The company targets unmet needs in psychiatry and other CNS segments by reformulating well-established drugs for improved patient outcomes. Products are commercialized globally through licensing agreements with leading pharma companies. Clinical results per program are not yet publicly available.[2][3][4]

Therapeutic areas: PsychiatryNeurology
Modalities: Reformulated small molecules (value-added medicines)Extended-release oral tablets[2][3][5]
Industry: Biotech

Drug pipeline

1 asset

TrazoFlex

Unknown

Partnerships

Recipharm AB (global CDMO partner for manufacturing and supply)[5][6]

Beyond the preview

Go deeper on Spektus Pharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spektus Pharma Inc..

Explore the full profile